Cardiovascular Safety of Non-Insulin Pharmacotherapy for Type 2 Diabetes

Cardiovascular Diabetology - United Kingdom
doi 10.1186/s12933-017-0499-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Cureus
2017English

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Cardiovascular Safety of Type 2 Diabetes Medications: Review of Existing Literature and Clinical Implications

Hormones
MedicineEndocrinologyMetabolismDiabetes
2016English

Pharmacotherapy in Type 1 Diabetes

Canadian Journal of Diabetes
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2013English

Reflections on Using Non-Inferiority Randomised Placebo Controlled Trials in Assessing Cardiovascular Safety of New Agents for Treatment of Type 2 Diabetes

Evidence-Based Medicine
Medicine
2017English

Cardiovascular Safety of Sitagliptin in Patients With Type 2 Diabetes Mellitus: A Pooled Analysis

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2013English

Insulin for Type 2 Diabetes: Choosing a Second-Line Insulin Regimen

International Journal of Clinical Practice
Medicine
2008English

Examining the Evidence for Self-Monitoring of Blood Glucose in Non-Insulin Type 2 Diabetes

Expert Review of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2011English

Efficacy and Safety of Weight Based Insulin Order for Blood Glucose Control of Type 2 Diabetes Mellitus

Journal of Gandhara Medical and Dental Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy